复方红豆杉胶囊治疗肝癌60例临床研究

Clinical Study on Compound Hongdoushan Capsules for Treatment of 60 Cases of Hepatic Cancer

目的:考察复方红豆杉胶囊在肝癌化疗中的增效作用及安全性。方法:将120例肝癌患者随机分为两组,治疗组60例除按常规化疗方案治疗外,加服复方红豆杉胶囊;对照组60例按常规化疗方案治疗。结果:两组近期疗效总有效率分别为81.67%和68.33%,治疗组显著优于对照组(P<0.05);治疗后两组患者肿瘤面积均有缩小,Karnofsky评分均有增加,但治疗组更为明显(P<0.01)。未发现骨髓抑制及其他副作用。结论:复方红豆杉胶囊具有明显的增效作用,并可提高肝癌化疗患者的生活质量,临床使用安全可靠。

Objective： To investigate the synergistic action and safety of Compound Hongdoushan Capsules for chemotherapy of hepatic cancer. Methods： 120 cases of hepatic cancer were randomly divided into two groups. The treatment group（n= 60） were treated with routine chemotherapy program plus Compound Hongdoushan Capsules, and the control group （n = 60） with routine chemotherapy program. Results：The short-term total effective rate was 81.67% and 68. 33% in treatment and control group respectively,the treatment group being significantly better than the control group （P〈0. 05）. The area of tumor was attenuated, and Karnofsky score increased in both groups,the treatment group being more（P〈0.01）. No arrest of bone marrow and other adverse effects was found. Conclusion：Compound Hongdoushan Capsules has obvious synergistic action, and it can raise quality of life of the patient with hepatic cancer.